Refine your search

Search Results within category "Skin Conditions"

Here are the studies that match your search criteria. If you are interested in participating, please reach out to the contact listed for the study. If no contact is listed, contact us and we'll help you find the right person.

Search all categories
23 Study Matches

Site For AbbVie- HS Surgery

Site For AbbVie- HS Surgery
Logan Claar at lclaar@pennstatehealth.psu.edu or 717-531-5136
All
18 year(s) or older
This study is NOT accepting healthy volunteers
N/A
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Must be able to travel to Hershey Medical Center for 12 visits
Must be diagnosed with HS for 1 year prior to study participation
Must be willing to perform self injections at home
Exclusion Criteria:
Prior treatment of Humira or other biologics for the treatment of HS
Skin Conditions
  Email this study information to me
  Contact the study team
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

A Phase 2b/3, Randomized, Double-Blind, Placebo-Controlled, 2-Arm, Efficacy, and Safety Study in Prurigo Nodularis with Nalbuphine ER Tables for Pruritus Relief Through Itch Scratch Modulation (PRISM Study)

Prurigo Nodularis: Phase 2b/3 Subject and Investigator Blinded, 56 Week study. Oral medication taken twice daily, Males/Females 18 years and older with Prurigo Nodularis Prurigo Nodularis (PN) is a skin disease that causes hard, itchy lumps (nodules) to form on the skin. The itching (pruritus) can be intense, cause people to scratch themselves to the point of bleeding or pain. The goal of this study is to evaluate the change of itch with using Nalbuphine ER.
Amy Longenecker at alongenecker@pennstatehealth.psu.edu or 717-531-5136
All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT03497975
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
PN involving 2 affected areas
Willing to follow all study directions and attend appointments
Exclusion Criteria:
PN affecting only 1 part of the body
Certain diagnosis associated with PN are not allowed, coordinator will discuss specifics
Skin Conditions
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Hidradenitis Suppurativa

Hidradenitis Suppurativa: Phase 2 Double-Blinded to Open-Label Study, up to 60 weeks long. Oral medication, Males/Females 18-75 years old with Hidradenitis Suppurativa (HS) for at least 3 months Hidradenitis Suppurativa (HS), is a long-lasting, inflammatory skin condition. HS is characterized by lesions that can be found most commonly in the groin, armpits, and buttocks. These lesions are very painful and can drain and cause scarring. The purpose of this study is to find out if the study drug, INCB054707 can help treat HS.
Amy Longenecker at alongenecker@pennstatehealth.psu.edu or 717-531-5136
All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT04476043
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
HS diagnosis for at least 3 months
HS lesions in at least 2 different areas
Willing to follow all study guidelines
Exclusion Criteria:
Certain treatments for HS are not allowed; coordinator will discuss specific treatments
Positive test results for HIV, hepatitis B, or hepatitis C
Skin Conditions
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

Exploratory Trial of Ruxolitinib 1.5% Cream for Early Stage Hidradenitis Suppurativa

Explore all stages of Hidradenitis Suppurativa with a topical medication.
Amy Longenecker at alongenecker@pennstatehealth.psu.edu or 717-531-5136
All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT04414514
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Must have diagnosis of HS for at least 3 months (90 days)
Must have active HS in at least 1 area
Must have negative TB screening assessment
Certain medications can be continued if on stable dose; study coordinator will discuss further.
Exclusion Criteria:
Any other active skin disease or condition that may interfere with assessment of HS
Pregnant (or considering becoming pregnant) or lactating females
Does not have reliable internet access for weekly electronic surveys
Skin Conditions
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

A Phase I, Single-Center, Double-Blind, Randomized Safety, Tolerability, and Dermal Reactogenicity Study of Higher Doses of PDC-APB in Healthy Volunteers With a History of Contact Dermatitis Due to Poison Ivy Exposure

Phase 1, Double- Blind Study, 15 week study, Patch test and Vaccine Injection, Males/Females 18-65 years old with history of urushiol exposure. The rash or allergic contact dermatitis of poison ivy is recognized as occurring after the exposure to the urushiol oil which is found in the leaves of poison ivy, oak and sumac. Currently there is no preventative treatment for contact dermatitis. The purpose of this study is to find out if the vaccine, PDC-APB can help with the prevention of contact dermatitis.
Amy Longenecker at alongenecker@pennstatehealth.psu.edu or 717-531-5136
All
18 year(s) or older
This study is also accepting healthy volunteers
N/A
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Documented history of Poison Ivy (urushiol) exposure with a rash
Willing to follow all study instructions
Attend all study visits
Exclusion Criteria:
use of certain medications not allowed; study coordinator will provide more information
Positive test result of HIV, Hepatitis B or Hepatitis C
Participation in an investigational drug or device study within 30 days prior to screening
There are over the counter medications that are not permitted during the study participation, the study coordinator will discuss the list during the screening process.
Skin Conditions
  Email this study information to me
  Contact the study team
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

A Phase 3 Efficacy and Safety Study of Tapinarof for the Treatment of Moderate to Severe Atopic Dermatitis in Children and Adults

Atopic Dermatitis: Phase 3 double-blinded study, 8 week study with potential rollover into an open label extension. Topical cream. Males/females 2 years and above with atopic dermatitis (AD) Atopic Dermatitis (AD), also known as eczema, is an inflammatory skin condition that can occur repeatedly. AD often causes itching and burning, skin flaking, and red bumps that can crust and open up. The purpose of this study is to find out if the study medicine, tapinarof cream, can help with the treatment of AD.
Samantha Gettle at sgettle2@pennstatehealth.psu.edu or 717-531-5136
All
All
This study is NOT accepting healthy volunteers
NCT05014568
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
AD present for at least 6 months for ages 6 and above, or 3 months for ages 2 to 5
AD covering between 5% and 35% body surface area
Willing to follow all study guidelines
Exclusion Criteria:
Positive test results for HIV
Current or chronic liver disease
Certain treatments for AD are not allowed; coordinator will discuss specific treatments
Skin Conditions
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

Site for A 12-Week Double-Blind, Placebo-Controlled Randomized Phase 2 Trial with a 12-Week Open-Label Extension to Determine the Immunomodulatory Activity of PTM-001 in Patients with Hidradenitis Suppurativa

Hidradenitis Suppurativa (HS): Assigned to PTM-001 (400mg) or placebo (no active ingredients) for 12 weeks after which all patients will receive the actual study medication, PTM-001 400mg daily for an additional 12 weeks. Males/Females 18 years of age and older. The goal of the study is assess the effect of PTM-001 on skin protein levels.
Amy Longenecker at alongenecker@pennstatehealth.psu.edu or 717-531-5136
All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT05020730
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Had onset of symptoms consistent with HS at least 6 months; active HS for at least 2 months
Agrees to follow all study directions
Exclusion Criteria:
Has other skin conditions that could interfere with viewing HS
Positive for TB, HIV, Hepatitis B or Hepatitis C
Certain medications not allowed; study coordinator will discuss
For females: Pregnant, nursing or considering becoming pregnant
Skin Conditions
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

A randomized, subject and investigator blinded, placebocontrolled and multi-center platform study, to assess efficacy and safety of different investigational drugs in patients with moderate to severe hidradenitis suppurativa

Hidradenitis Suppurativa: Phase 2 Subject and Investigator Blinded, 7 and a half month study. Platform Study: Injectable and Oral drug, Males/Females 18-65 years old with Hidradenitis Suppurativa. Hidradenitis Suppurativa (HS) is a chronic recurrent and debilitating skin condition that typically presents with deep and painful lesions. The most common areas affected are the armpits, the groin, and the anus and genitals area. The purpose of the study is to find out if the study drugs (iscalimab and LYS006) are beneficial and safe in patients with HS.
Samantha Gettle at sgettle2@pennstatehealth.psu.edu or 717-531-5136
All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT03827798
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
HS diagnosis for at least 1 year
HS lesions in at least 2 affected areas
Exclusion Criteria:
Prior treatment to certain medications
Skin Conditions
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Bimekizumab in Study Participants with Moderate to Severe Hidradenitis Suppurativa

Hidradenitis Suppurativa: Phase 3 Double-Blind Study. Participation will last approximately 71 weeks. Injection under the skin, Males/Females at least 18 years old with Hidradenitis Suppurativa (HS) Hidradenitis Suppurativa (HS), is an inflammatory skin condition that can come and go. It is characterized by painful spots, called lesions, that are found most commonly in the groin, armpits, and buttocks. These lesions are very painful and can drain and cause scarring. The purpose of this study is to find out if the study medicine, bimekizumab, can help with the treatment of HS.
Amy Longenecker at alongenecker@pennstatehealth.psu.edu or 717-531-5136
All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT04242446
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
HS lesions present in at least 2 locations (armpits, under breast, abdomen, groin, buttock),
Diagnosed with HS for at least 6 months
failed antibiotic treatment for HS
Exclusion Criteria:
certain medication are not allowed; study coordinator will provide more information
Diagnosis of sarcoidosis, Systemic lupus erythematosus, or active IBD
Have had a splenectomy
Positive test result for Hepatitis B or Hepatitis C
Have had major surgery in the past 3 months
Skin Conditions
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

Site for A Phase 3, 4-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-151 Cream 0.05% Administered QD in Subjects with Atopic Dermatitis

Atopic Dermatitis: Double Blind, 4 weeks study. Topical Cream applied daily. Males/Females 2-5 years with mild to moderate atopic dermatitis. At the week 4 visit subjects may be eligible to enroll in a 12-month, open label extension study. The goal of the study is assess the safety and effectiveness of ARQ-151 0.05% cream.
Amy Longenecker at alongenecker@pennstatehealth.psu.edu or 717-531-5136
All
Younger than 18 years old
This study is NOT accepting healthy volunteers
NCT04844562
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Must be 2-5 years of age
Exclusion Criteria:
certain medications/treatments are not allowed; study coordinator will discuss further
Subjects currently undergoing allergy testing (food allergy testing or skin prick testing), patch testing, food challenges, or allergy desensitization, or plan to do so during the study
Skin Conditions
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

Site for A Phase 2a, Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ATI-450 vs Placebo in Patients with Moderate to Severe Hidradenitis Suppurativa (HS)

Moderate to Severe Hidradenitis Suppurativa (HS): Placebo-Controlled (non active ingredient), 12-week treatment period. Oral medicine taken twice daily. Males/Females 18 - 70 years of age. The goal of the study is assess the efficacy (desired or intended result) of ATI-450 in patients with moderate to severe HS
Amy Longenecker at alongenecker@pennstatehealth.psu.edu or 717-531-1513
All
18 year(s) or older
This study is NOT accepting healthy volunteers
N/A
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
History of HS for at least 1 year
Must have HS lesions in 2 different areas
Exclusion Criteria:
Certain HS medications are not allowed; study coordinator will discuss
History of stroke
Positive for HIV or hepatitis B or C
Skin Conditions
  Email this study information to me
  Contact the study team
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

Site for A randomized, double blind, vehicle-controlled, multicenter Phase II study to evaluate the safety and efficacy of BF-200 ALA (Ameluz) and BF-RhodoLED in the treatment of moderate to severe Acne vulgaris in adults with photodynamic therapy (PDT)

Moderate to Severe Acne Vulgaris: Males/Females 16 years and older. You will receive the study drug with either 1 hour or 3 hours between study drug application and illumination. The purpose of this study is to test the effectiveness and safety of the study drug, used at two different incubation times (time starting with administration of study drug until start of the red light illumination).
Amy Longenecker at alongenecker@pennstatehealth.psu.edu or 717-531-5136
All
All
This study is NOT accepting healthy volunteers
NCT05080764
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Ages 16 years and older may be eligible to participate.
willingness to stop topical facial treatments other than medical cleansers at least 14 days prior to receiving investigational product.
For females must use an adequate and highly effective or two effective methods of contraception throughout the study. Study coordinator will discuss.
Exclusion Criteria:
History of soy or peanut allergy.
For males- beard or other facial hair that might interfere with the study assessments unless subject agrees to be clean-shaven throughout the entire study period.
Certain medications/treatments not allowed during the study; study coordinator will discuss.
Skin Conditions
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

Site for A RANDOMIZED, DOUBLE-BLIND, MULTI-CENTER COMPARATIVE EFFECTIVENESS STUDY OF SPIRONOLACTONE VERSUS DOXYCYCLINE HYCLATE FOR THE TREATMENT OF ACNE IN WOMEN

Mild to Severe Acne: Women ages 16-40 years. Assigned to either spironolactone of doxycycline; oral medication taken once daily. The duration of the study will last 16 weeks. During that time participants will attend 3 in person study visits (study start, week 8 and week 16). In addition participants will completion questions outside of study visits at Week 4 and Week 12. The goal of this trial is to compare the effectiveness of spironolactone and doxycycline hyclate in the treatment of acne in women.
Amy Longenecker at alongenecker@pennstatehealth.psu.edu or 717-531-5136
Female
All
This study is NOT accepting healthy volunteers
NCT04582383
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Assigned female at birth; ages 16-40 years old
Birth control options will be discussed by study coordinator
Exclusion Criteria:
Certain acne treatments are not allowed; study coordinator will discuss
Certain medical history conditions are not allowed; study coordinator will discuss
Skin Conditions
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

Defining the cellular and molecular signatures that are associated with the clinical heterogeneity of hidradenitis suppurativa

Patients with the clinical diagnosis of mild, moderate to severe Hidradenditis Suppurativa or normal healthy volunteers ages 18 and older to participate in a 1 time study visit. There is no treatment provided but we may gain information for the treatment of HS.
Amy Longenecker at alongenecker@pennstatehealth.psu.edu or 717-531-1513
All
18 year(s) or older
This study is also accepting healthy volunteers
N/A
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
18 years and older
Hidradentitis Suppurativa diagnosis for 3 months
Normal skin participants
Exclusion Criteria:
Patients who are Pregnant
Normal skin participants do not have an autoimmune disease
Participants who do not want to have any of the lesion sampling performed
Skin Conditions
  Email this study information to me
  Contact the study team
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

Associations of dietary preferences with management of HS symptoms

We will be examining the diets of people with hidradenitis suppurativa to see if they consume different amounts of foods like dairy, tomatoes, or gluten.
Melissa Butt at mbutt1@pennstatehealth.psu.edu
All
18 year(s) or older
This study is NOT accepting healthy volunteers
N/A
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
People who have a history of hidradenitis suppurativa
Seen at Penn State Health within the past year
18 years of age or older
Can read/write in English
Have access to the internet
Exclusion Criteria:
Those who do not meet inclusion criteria
Skin Conditions, Food & Nutrition
  Email this study information to me
  Contact the study team

Assessing the treatment of scalp conditions in adult patients

This study is aiming to identify the differences in medicated hair care practices amongst adult patients with scalp conditions. Typical treatment for scalp conditions involves the continued use of medicated shampoos; however, hair care practices across all ethnic and racial barriers are different. This could impact the effectiveness of these medicated washes if they are by chance not being used frequently enough. To our knowledge, no research has explored hair care practices and their relationship to dermatological conditions that affect the scalp.
Tierney Wallace at twallace3@pennstatehealth.psu.edu
All
18 year(s) or older
This study is NOT accepting healthy volunteers
N/A
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Over 18
Access to email and internet
Have sebhorreic dermatitis, sebopsoriasis, dandruff, or psoriasis of the scalp
Exclusion Criteria:
Any other skin conditions
Any scalp conditions with open wounds or sores
Skin Conditions
  Email this study information to me
  Contact the study team

Site for A Multicenter, Open-Label, Single Group Clinical Trial to Assess the Pharmacokinetics, Safety and Efficacy of Nemolizumab (CD14152) in Pediatric Subjects (aged 2 to 11 years) with Moderate-to-Severe Atopic Dermatitis

Atopic Dermatitis: Open Label, 64 weeks study. Injectable medicine. Males/Females 2-11 years with moderate to severe atopic dermatitis. The goal of the study is assess the uptake of the drug by the body and safety of nemolizumab administered with topical corticosteroids.
Amy Longenecker at alongenecker@pennstatehealth.psu.edu or 717-531-5136
Female
Younger than 18 years old
This study is NOT accepting healthy volunteers
NCT04921345
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Ages 2-11 years old
Diagnosed with Moderate to Severe Atopic Dermatitis
Willing to attend all study visits and follow directions
Exclusion Criteria:
Certain treatments for atopic dermatitis are not allowed; study coordinator will discuss
Had a documented asthma exacerbation requiring hospitalization in the past 12 months.
Weigh less than 22 pounds
Skin Conditions
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

Site for A Multicenter, Phase 2B, Randomized, Double-Blind, Stratified, Vehicle-Controlled Study Evaluating the Safety and Efficacy of Sirolimus 3.9% Topical Gel in Prevention of BCCs in Patients with Gorlin Syndrome

Gorlin Syndrome: Topical gel applied daily before bedtime. Approximately 32 week participation. 18 years and older meeting diagnostic criteria for Gorlin Syndrome. The goal of this study is to compare the number of new biopsy confirmed BCCs that develop over a 6-month period between the treatment arms, active and placebo (no active indgredient). This study will also include disease burden assessments (questionnaires) at various timepoints.
Amy Longenecker at alongenecker@pennstatehealth.psu.edu or 717-531-5136
All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT04893486
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Wiling to abstain from application of a non-study topical medication (prescription or over the counter) to face for the duration of the trial.
Willing to have blood collected.
Willing to follow all study instructions.
Must have had at least 10 basal cells present on the face, scalp, and/or neck within past 24 months.
Exclusion Criteria:
>20 clinically suspicious lesions on the face at time of randomization.
Certain Medications are not allowed; study coordinator will discuss.
Previously participated in a clinical trial evaluating an investigational product for treatment of BCCs or GS within the past 3 months.
Skin Conditions
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

Site for An Open-label Multiple Dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Upadaticinib in Pediatric Subjects with Severe Atopic Dermatitis

Phase 1, multiple-dose, open-label study consisting of two parts, male and female subjects aged 2 to 12 years with severe atopic dermatitis (eczema).
Samantha Gettle at sgettle2@pennstatehealth.psu.edu or 717-531-5136
All
Younger than 18 years old
This study is NOT accepting healthy volunteers
NCT03646604
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
must weight 22 pounds or more
Have a diagnosis of Atopic Dermatitis for at least 6 months
Exclusion Criteria:
Certain treatments are not allowed; coordinator will discuss specific treatments
No active Hep A, Hep C or Hep B
Current participation in another clinical trial
Skin Conditions
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Children (Ages ≥ 2 Years to < 12 Years) With Atopic Dermatitis

Atopic Dermatitis (AD): Phase 3 double-blinded study, 8 week study with 44 week long-term safety period with guaranteed study medicine. Topical cream. Male and females ≥ 2 Years to < 12 Years with AD Atopic Dermatitis (AD), also known as eczema, is an inflammatory skin condition that can reoccur repeatedly. AD often causes itching and burning, skin flaking, and red bumps that can crust and open up. The purpose of this study is to find out of the study medicine, ruxolitinib cream, can help with the treatment of AD.
Samantha Gettle at sgettle2@pennstatehealth.psu.edu or 717-531-5136
All
Younger than 18 years old
This study is NOT accepting healthy volunteers
NCT04921969
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
AD present for at least 3 months
AD covering between 3% and 20% body surface
Willing to follow all study guidelines
Exclusion Criteria:
Certain treatments for AD are not allowed; coordinator will discuss specific treatments
Positive for Hepatitis B, Hepatitis C, or HIV
Previous treatment with JAK inhibitors
Skin Conditions
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

A Phase 2a/2b, Multicenter, Randomized, Placebo and Active Comparator-controlled, Double-Blind, Dose-ranging Study to Evaluate the Safety and Efficacy of Bermekimab (JNJ-77474462) for the Treatment of Subjects with Moderate to Severe Hidradenitis Suppurativa

Hidradenitis Suppurativa (HS) is a reoccurring, inflammatory skin condition. HS is known for lesions most commonly found in the groin, armpits, and buttocks. These lesions are very painful and can drain and cause scarring. The purpose of this study is to find out if the study medicine, bermekimab, can help with the treatment of HS.
Samantha Gettle at sgettle2@pennstatehealth.psu.edu or 717-531-4439
All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT04988308
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
HS diagnosis for at least 1 year
HS lesions in at least 2 different areas
Willing to follow all study guidelines
Exclusion Criteria:
Certain treatments for HS are not allowed; coordinator will discuss specific treatments
Positive test results for HIV, hepatitis B, or hepatitis C
Unstable cardiovascular disease
Skin Conditions
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

Site for A Phase 3, 4-Week, Parallel Group, Double-Blind, Vehicle- Controlled, Study of the Safety and Efficacy of ARQ-151 Cream 0.15% Administered QD in Subjects with Atopic Dermatitis

Atopic Dermatitis: Phase 3 Double Blind, Vehicle-Controlled Study. Participation will last approximately 8 weeks. Topical cream will be applied once a day, Males/Females at least 6 years old with mild to moderate atopic dermatitis Atopic Dermatitis is a chronic inflammatory skin disorder affecting children and adults, with the majority presenting with disease of mild to moderate severity. The purpose of this study is to find out if the study medicine, ARQ-151 0.15% cream vs vehicle cream is safe for subjects with atopic dermatitis
Amy Longenecker at alongenecker@pennstatehealth.psu.edu or 717-531-1513
All
All
This study is NOT accepting healthy volunteers
NCT04773600
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
History of Atopic Dermatitis for at least 3 months in subjects 6-17 years or age
History of Atopic Dermatitis for at least 6 months in subjects 18 years and older.
Willing to attend all study visits and follow directions
Exclusion Criteria:
Certain treatments for Atopic Dermatitits are not allowed; study coordinator will discuss
Subjects currently undergoing allergy testing
Skin Conditions
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

A prospective, observational cohort study to assess flares in participants with hidradenitis suppurativa

This is a questionnaire study to establish new ways to measure HS flares. Subjects and providers will each complete questionnaires at regularly occurring visits.
Amy Longenecker at alongenecker@pennstatehealth.psu.edu or 717-531-5136
All
18 year(s) or older
This study is NOT accepting healthy volunteers
N/A
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Confirmed diagnosis of hidradenitis suppurativa (HS)
Active HS within 3 months of baseline
Reliable internet access on a phone or computer
Exclusion Criteria:
No reliable internet access
Not fluent in English
Mental impairment that would prevent you from understanding and responding to questionnaires
Skin Conditions
  Email this study information to me
  Contact the study team
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA